TALPHERA, INC. Net Income (Loss) Available to Common Stockholders, Diluted
TALPHERA, INC. (TLPH) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$18.40 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2024-03-06
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-12-31 was -$4.52M.
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$1.36M.
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$4.37M, a 106.92% decline year-over-year.
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2023-03-31 was -$8.15M.
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$18.40M, a 143.45% decline from fiscal 2022.
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was $42.34M.
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$51.51M.
- TALPHERA, INC. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$43.16M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | -$4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$5.87M derived: sum of 2 quarters · filed 2024-03-06 | -$10.24M derived: sum of 3 quarters · filed 2024-03-06 | -$18.40M 10-K · filed 2024-03-06 | |
| 2023-09-30 | -$1.36M 10-Q · filed 2023-11-14 | -$5.73M derived: sum of 2 quarters · filed 2023-11-14 | -$13.88M 10-Q · filed 2023-11-14 | -$20.62M derived: sum of 4 quarters · filed 2024-03-06 | |
| 2023-06-30 | -$4.37M 10-Q · filed 2023-08-10 | -$12.52M 10-Q · filed 2023-08-10 | -$19.26M derived: sum of 3 quarters · filed 2024-03-06 | -$26.20M derived: sum of 4 quarters · filed 2024-03-06 | |
| 2023-03-31 | -$8.15M derived: 10-K 12 month − 3 quarters · filed 2024-03-06 | -$14.89M derived: sum of 2 quarters · filed 2024-03-06 | -$21.82M derived: sum of 3 quarters · filed 2024-03-06 | $41.33M derived: sum of 4 quarters · filed 2024-03-06 | |
| 2022-12-31 | -$6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$13.67M derived: sum of 2 quarters · filed 2024-03-06 | $49.48M derived: sum of 3 quarters · filed 2024-03-06 | $42.34M 10-K · filed 2024-03-06 | |
| 2022-09-30 | -$6.94M 10-Q · filed 2023-11-14 | $56.22M derived: sum of 2 quarters · filed 2023-11-14 | $49.08M 10-Q · filed 2023-11-14 | $54.92M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $63.16M 10-Q · filed 2023-08-10 | $55.37M 10-Q · filed 2023-08-10 | |||
| 2021-12-31 | -$7.92M derived: 8-K 12 month − 10-Q 9 month · filed 2023-08-01 | -$16.29M derived: sum of 2 quarters · filed 2023-08-01 | -$35.10M 8-K · filed 2023-08-01 | ||
| 2021-09-30 | -$8.38M 10-Q · filed 2022-11-14 | -$27.18M 10-Q · filed 2022-11-14 | |||
| 2017-12-31 | -$51.51M 10-K · filed 2018-03-09 | ||||
| 2017-06-30 | -$13.06M 10-Q · filed 2017-08-02 | -$28.61M 10-Q · filed 2017-08-02 | -$38.29M derived: sum of 3 quarters · filed 2018-03-09 | -$49.69M derived: sum of 4 quarters · filed 2018-03-09 | |
| 2017-03-31 | -$15.55M 10-Q · filed 2017-05-08 | -$25.23M derived: sum of 2 quarters · filed 2018-03-09 | -$36.63M derived: sum of 3 quarters · filed 2018-03-09 | -$47.73M derived: sum of 4 quarters · filed 2018-03-09 | |
| 2016-12-31 | -$9.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$21.08M derived: sum of 2 quarters · filed 2018-03-09 | -$32.18M derived: sum of 3 quarters · filed 2018-03-09 | -$43.16M 10-K · filed 2018-03-09 | |
| 2016-09-30 | -$11.40M 10-Q · filed 2016-11-02 | -$22.49M derived: sum of 2 quarters · filed 2017-08-02 | -$33.48M 10-Q · filed 2016-11-02 | -$44.07M derived: sum of 4 quarters · filed 2018-03-09 | |
| 2016-06-30 | -$11.09M 10-Q · filed 2017-08-02 | -$22.07M 10-Q · filed 2017-08-02 | -$32.67M derived: sum of 3 quarters · filed 2018-03-09 | -$27.88M derived: sum of 4 quarters · filed 2018-03-09 | |
| 2016-03-31 | -$11.31M 10-Q · filed 2017-05-08 | -$21.58M derived: sum of 2 quarters · filed 2018-03-09 | -$16.79M derived: sum of 3 quarters · filed 2018-03-09 | -$25.69M derived: sum of 4 quarters · filed 2018-03-09 | |
| 2015-12-31 | -$10.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$5.48M derived: sum of 2 quarters · filed 2018-03-09 | -$14.38M derived: sum of 3 quarters · filed 2018-03-09 | -$26.52M 10-K · filed 2018-03-09 | |
| 2015-09-30 | $4.79M 10-Q · filed 2016-11-02 | -$4.11M derived: sum of 2 quarters · filed 2016-11-02 | -$16.25M 10-Q · filed 2016-11-02 | -$28.89M derived: sum of 4 quarters · filed 2017-03-03 | |
| 2015-06-30 | -$8.90M 10-Q · filed 2016-07-29 | -$21.04M 10-Q · filed 2016-07-29 | -$33.67M derived: sum of 3 quarters · filed 2017-03-03 | -$39.42M derived: sum of 4 quarters · filed 2017-03-03 | |
| 2015-03-31 | -$12.21M 10-Q · filed 2016-05-02 | -$24.78M derived: sum of 2 quarters · filed 2017-03-03 | -$30.52M derived: sum of 3 quarters · filed 2017-03-03 | -$43.61M derived: sum of 4 quarters · filed 2017-03-03 | |
| 2014-12-31 | -$12.56M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$18.31M derived: sum of 2 quarters · filed 2017-03-03 | -$31.39M derived: sum of 3 quarters · filed 2017-03-03 | -$40.34M 10-K · filed 2017-03-03 | |
| 2014-09-30 | -$5.75M 10-Q · filed 2015-11-03 | -$18.83M derived: sum of 2 quarters · filed 2015-11-03 | -$27.78M 10-Q · filed 2015-11-03 | ||
| 2014-06-30 | -$13.08M 10-Q · filed 2015-08-04 | -$22.03M 10-Q · filed 2015-08-04 | |||
| 2014-03-31 | -$9.63M 10-Q · filed 2015-05-05 | ||||
| 2013-12-31 | -$23.43M 10-K · filed 2016-03-07 | ||||
| 2012-12-31 | -$33.36M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |